Royalty Pharma Revises Conditions Of $6B Elan Takeover
Royalty Pharma AG said Thursday that it would lower the threshold for shareholder acceptance of its $6.3 billion hostile takeover bid for U.K. drugmaker Elan Corp. from 90 to 50 percent...To view the full article, register now.
Already a subscriber? Click here to view full article